The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety
- PMID: 15450340
- DOI: 10.1016/j.det.2003.12.002
The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety
Abstract
It is quite evident the pathogenesis of psoriasis is modulated by immune-mediated mechanisms that invoke activated T cells and inflammatory cytokines, such as tumor necrosis factor-alpha. Current immunosuppressive systemic treatments may be effective in controlling psoriasis to a certain degree but have significant drawbacks, such as toxicity and relapse of the disease on discontinuation. The advantages of biologic agents are their greater selectivity in targeting specific pathways in the inflammatory cascade of psoriasis with a much higher safety profile. With specific antagonism directed against tumor necrosis factor-alpha, etanercept has demonstrated remarkable efficacy in the treatment of psoriasis and psoriatic arthritis.
Similar articles
-
Etanercept for psoriasis in the pediatric population: experience in nine patients.Pediatr Dermatol. 2006 Jan-Feb;23(1):67-71. doi: 10.1111/j.1525-1470.2006.00174.x. Pediatr Dermatol. 2006. PMID: 16445417
-
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.J Dermatolog Treat. 2006;17(6):355-8. doi: 10.1080/09546630601028703. J Dermatolog Treat. 2006. PMID: 17853309 Clinical Trial.
-
Etanercept for the treatment of psoriasis: combination therapy with other modalities.J Drugs Dermatol. 2004 May-Jun;3(3):270-2. J Drugs Dermatol. 2004. PMID: 15176161
-
Etanercept therapy in patients with autoimmunity and hepatitis C.J Dermatolog Treat. 2003 Dec;14(4):229-32. doi: 10.1080/09546630310020470. J Dermatolog Treat. 2003. PMID: 14660270 Review.
-
Etanercept for the treatment of psoriasis.Skin Therapy Lett. 2006 Feb;11(1):1-4. Skin Therapy Lett. 2006. PMID: 16485060 Review.
Cited by
-
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab.Arch Dermatol Res. 2006 Dec;298(7):329-38. doi: 10.1007/s00403-006-0694-9. Epub 2006 Sep 21. Arch Dermatol Res. 2006. PMID: 17021768 Free PMC article. Clinical Trial.
-
Update of the management of chronic psoriasis: new approaches and emerging treatment options.Clin Cosmet Investig Dermatol. 2010 Apr 21;3:25-37. doi: 10.2147/ccid.s6497. Clin Cosmet Investig Dermatol. 2010. PMID: 21437057 Free PMC article.
-
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature.Dermatol Ther (Heidelb). 2019 Jun;9(2):373-381. doi: 10.1007/s13555-019-0290-5. Epub 2019 Mar 16. Dermatol Ther (Heidelb). 2019. PMID: 30879179 Free PMC article.
-
Current and emerging systemic treatment strategies for psoriasis.Drugs. 2012 Oct 1;72(14):1867-80. doi: 10.2165/11634980-000000000-00000. Drugs. 2012. PMID: 22938141 Review.
-
Drug therapies in dermatology.Clin Med (Lond). 2014 Feb;14(1):47-53. doi: 10.7861/clinmedicine.14-1-47. Clin Med (Lond). 2014. PMID: 24532745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical